Stockwatch: Age And Outcome Duration Cloud Innovative Therapy Reimbursement
$1m-Plus For Gene And Cellular Therapies Hard To Swallow When Patients’ Responses Differ
Executive Summary
Gene and cellular therapies that can replace decades of expensive therapy do not come cheap. Even the initial remedy of payment by installments could be irrelevant when not all patients respond in the same way.
You may also be interested in...
BioMarin’s Hemophilia Gene Therapy Still Works After Four Years, But Effects Tail Off
Latest results show a show decline in effects, but still offers freedom from injections with almost no bleeds recorded in 13 patients.
Sarepta’s Gene Therapy Impresses In Limb-Girdle Muscular Dystrophy
Positive functional results from Sarepta’s SRP-9003 gene therapy in limb-girdle muscular dystrophy type 2E bodes well for a pivotal study, and for the company’s studies of other potential gene therapies in Duchenne muscular dystrophy.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.